Nexavar fails recurrence target

Share this article:
Nexavar fails recurrence target
Nexavar fails recurrence target

Phase-III tests using oncology drug Nexavar as an adjuvant therapy for liver cancer failed to meet a recurrence-free survival target. Partners Bayer and Amgen's Onyx division announced the results Tuesday, and said they will detail results of the STORM clinical trial at a scientific conference.

Amgen funds 50% of Nexavar R&D costs and co-promotes the drug with Bayer in the US through its own sales force and medical science liaisons.

The 1,100 patient trial assessed cancer patients who appeared cancer-free after surgical resection or ablation. These patients received 400mg of sorafenib or a placebo for four years, or until the cancer returned. The drug was one of Bayer's top-selling pharmaceuticals in 2013, earning $1 billion in 2013, behind contraceptive Yaz, which ranked fourth among last year's best sellers. While on Bayer's hit-list, higher US prices helped keep sales high, yet still slipped 2.7% compared to sales in 2012.

The drug's approved indications include advanced renal cell carcinoma (2005) and unresectable hepatocellular carcinoma (2007). The FDA approved Nexavar for locally recurrent or metastatic, progressive differentiated thyroid cancer refractory to iodine under priority review in November.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...